Neuropediatrics 2006; 37(3): 137-141
DOI: 10.1055/s-2006-924555
Original Article

Georg Thieme Verlag KG Stuttgart · New York

Acute Flaccid Paralysis as Initial Symptom in 4 Patients with Novel E1α Mutations of the Pyruvate Dehydrogenase Complex

H. M. Strassburg1 , J. Koch2 , J. Mayr2 , W. Sperl2 , E. Boltshauser3
  • 1University Children's Hospital Würzburg, Germany
  • 2Children's Hospital, Paracelsus Private Medical University, Salzburg, Austria
  • 3University Children's Hospital, Zürich, Switzerland
Further Information

Publication History

Received: March 21, 2006

Accepted after Revision: August 8, 2006

Publication Date:
11 September 2006 (online)

Abstract

We report on 4 boys from 3 families presenting initially in infancy with an acute onset of flaccid tetraparesis and areflexia, resembling Guillain-Barré syndrome (GBS). However, the cerebrospinal fluid (CSF) protein was normal, while serum and CSF lactate were elevated. All patients had recurrent similar episodes, usually associated with infections. Brain MRI showed T2 hyperintensities in the basal ganglia in two boys, in one of them at the first clinical presentation; the other one had a normal brain MRI during the first episode. A third boy had a normal MRI twice but an increased lactate peak in the basal ganglia in 1H‐MR spectroscopy. Motor nerve conduction velocities (NCV) were normal in all patients. Biochemical analyses of muscle tissue, performed in two patients, revealed a deficiency of the pyruvate dehydrogenase (PDH). Molecular genetic analysis of the X-chromosomal E1α subunit of PDH showed three new mutations in phylogenetically conserved areas of the protein: Glu358Lys in patient 1; Arg88Lys in patient 2 and 3 (brothers); and Leu216Ser in patient 4. In conclusion, children with “atypical GBS” should be evaluated for a mitochondrial disorder, including pyruvate dehydrogenase deficiency, even after a first episode.

References

  • 1 Ammache Z, Afifi A K, Brown C K, Kimura J. Childhood Guillain-Barré syndrome: clinical and electrophysiological features predictive of outcome.  J Child Neurol. 2001;  16 477-483
  • 2 Bonne G, Benelli C, De Meirleir L. et al . E1 pyruvate dehydrogenase deficiency in a child with motor neuropathy.  Pediatr Res. 1993;  33 284-288
  • 3 Brown M, Wallace D. Molecular basis of mitochondrial DNA disease.  J Bioenerg Biomembr. 1994;  26 273-289
  • 4 Chabrol B, Mancini J, Benelli C. et al . Leigh syndrome: Pyruvate dehydrogenase defect. A case with peripheral neuropathy.  J Child Neurol. 1994;  49 52-55
  • 5 Coker S B. Leigh disease presenting as Guillain-Barré syndrome.  Pediatr Neurol. 1993;  9 61-63
  • 6 Finsterer J. Mitochondrial neuropathy.  Clin Neurol Neurosurg. 2005;  107 181-185
  • 7 Gillis L, Kaye E. Diagnosis and management of mitochondrial diseases.  Pediatr Gastroenterol Nutrition. 2002;  49 203-219
  • 8 Gropman A L. Diagnosis and treatment of childhood mitochondrial diseases.  Curr Neurol Neurosci Report. 2001;  185-194
  • 9 Grunnet M L, Zalneraitis E L, Russman B S, Barwick M C. Juvenile Leigh's encephalomyelopathy with peripheral neuropathy, myopathy, and cardiomyopathy.  J Child Neurol. 1991;  6 159-163
  • 10 Hughes R A, Cornblath D R. Guillain-Barré syndrome.  Lancet. 2005;  366 1653-1666
  • 11 Jacobs J M, Harding B N, Lake B D. et al . Peripheral neuropathy in Leigh's disease.  Brain. 1990;  113 447-462
  • 12 Korinthenberg R, Moenting J S. Natural history and treatment effects in Guillain-Barré syndrome: a multicentre study.  Arch Dis Child. 1996;  74 281-287
  • 13 Lissens W, Meirleir D L, Sebeca S. et al . Mutation in the X-linked pyruvate dehydrogenase (E1) a subunit gene (PDHA1) in patients with a pyruvate dehydrogenase complex deficiency.  Human Mutat. 2000;  15 209-219
  • 14 Malandrini A, Palmeri S, Fabrizi G M. et al . Juvenile Leigh syndrome with protracted course presenting as chronic sensory motor neuropathy, ataxia, deafness and retinitis pigmentosa: A clinical pathological report.  J Neurol Sci. 1998;  155 218-221
  • 15 Marsac C, Benelli C, Desguerre I. et al . Biochemical and genetic studies of four patients with pyruvate dehydrogenase E1α deficiency.  Hum Genet. 1997;  99 785-792
  • 16 Munnich A, Rustin R. Clinical spectrum and diagnosis of mitochondrial disorders.  Am J Med Genet. 2001;  106 4-17
  • 17 Naito E, Ito M, Yokota I, Saijo T, Matsuda J, Ogawa Y, Kitamura S, Takada E, Horii Y, Kuroda Y. Thiamine-responsive pyruvate dehydrogenase deficiency in two patients caused by a point mutation (F205 L and L216F) within the thiamine pyrophosphate binding region.  Biochim Biophys Acta. 2002;  1588 79-84
  • 18 Sperl W, Ruitenbeek W, Sengers R CA. et al . Combined deficiencies of the pyruvate dehydrogenase complex and enzymes of respiratory chain in mitochondrial myopathies.  Eur J Pediatr. 1992;  151 192-195
  • 19 Sperl W, Trijbels J M, Ruitenbeek W, van Laack H L, Janssen A J, Kerkhof C M, Sengers R C. Measurement of totally activated pyruvate dehydrogenase complex activity in human muscle: evaluation of a useful assay.  Enzyme Protein. 1993;  47 37-46
  • 20 Stickler D, Carney P R, Valenstein E R. Juvenile-onset Leigh syndrome with acute polyneuropathy at presentation.  J Child Neurol. 2003;  18 574-576
  • 21 Stickler D E, Valenstein E, Neiberger R E. et al . Peripheral neuropathy in genetic mitochondrial diseases.  Pediatr Neurol. 2006;  34 127-131
  • 22 Valanne L, Ketonen L, Majander A. et al . Neuroradiologic findings in children with mitochondrial disorders.  Am J Neuroradiol. 1998;  19 369-377

Prof. Dr. E. Boltshauser

University Children's Hospital

Steinwiesstrasse 75

8032 Zürich

Switzerland

Email: eugen.boltshauser@kispi.unizh.ch